EFFICACY OF METHOTREXATE MICROINFUSION IN SCALP LESIONS OF PATIENTS WITH FIBROSING FRONTAL ALOPECIA: A PROSPECTIVE CONTROLLED TRIAL / EFICÁCIA DA MICROINFUSÃO DE METOTREXATO EM LESÕES DO COURO DE PACIENTES COM ALOPECIA FIBROSANTE: ENSAIO CLÍNICO PROSPECTIVO CONTROLADO

Introdução: A alopecia frontal fibrosante (AFF) é uma cicatriz linfocítica, com queda de cabelo pela linha de implantação frontal do couro cabeludo e outras áreas do corpo. Drogas tópicas e sistêmicas, como casos o MTX, não controlam a atividade da doença na maioria dos casos, a necessidade de novas terapias. Objetivo: Avaliar a diligência da microinfusão de metotrexato em AFF. Métodos: Ensaio clínico prospectivo, controlador, realizado com 17 voluntários com 1 diagnóstico clínico e histológico de AFF. As aplicações de MTX por MMP® (método de microinfusão de pele) foram feitas a cada 30 dias, num total de 3 aplicações, na direita da área de alopecia; a outra metade serviu como controle.medidas frontais glalares e parciais, dermatoscópicas, índice de avaliação externa dos olhos, a percepção do plano dos sinais do paciente (LPPAI). Hemograma total e testes de função hepática também foram médios. Resultados: Houve uma redução significativa nas medidas fronto-glabela e frontal temporo-parietal no local tratado, enquanto no local nãou a AAF aumentou. A paciente refere melhora do prurido e descamação, mas não da queda de cabelo e eritema local. A das fotos dermatoscópicas e a análise do LPPAI não são relevantes. Cerca de 9 participantes e todos nós não resultaram em 5% dos resultados com nenhum resultado de nenhum dos exames.Conclusão: A aplicação de MTX por MMP® melhorou os sintomas associados à AFF e as medidas fronto-glabela e fronto-parietal.

Introdução: A alopecia frontal fibrosante (AFF) é cicatricial linfocítica, com queda de cabelo pela linha de implantação frontal do couro cabeludo e outras áreas do corpo. Drogas tópicas e sistêmicas, como o metotrexato (MTX), não controlam a atividade da doença na maioria dos casos, mostrando a necessidade de novas terapias. Objetivo: Avaliar a eficácia da microinfusão de metotrexato em AFF. Métodos: Ensaio clínico prospectivo, controlado, realizado com 17 voluntários com diagnóstico clínico e histológico de AFF. As aplicações de MTX por MMP® (método de microinfusão de drogas na pele) foram feitas a cada 30 dias, totalizando 3 aplicações, na metade direita da área da alopecia; a outra metade serviu como controle. Foram avaliadas as medidas frontoglabela e frontal temporoparietal. Fotos de dermatoscopia foram analisadas por avaliadores cegos e externos com percepção de sinais e sintomas do paciente e o Índice de Atividade do Líquen Planopilar (LPPAI). Hemograma total e testes de função hepática também foram medidos. Resultados: Houve redução significativa nas medidas frontoglabela e frontal temporoparietal no local tratado, enquanto no não tratado a AAF aumentou. Houve melhora do prurido e descamação, mas não da queda de cabelo e eritema local. A análise das fotos dermatoscópicas e o cálculo do LPPAI não mostraram alterações relevantes. Cerca de 95% dos participantes ficaram satisfeitos ou muito satisfeitos com os resultados e nenhum deles teve alteração nos resultados dos exames laboratoriais. Conclusão: A aplicação de MTX por MMP® melhorou os sintomas associados à AFF e as medidas frontoglabela e frontoparietal. Esta técnica mostrou-se segura e bem tolerada.

Fenómeno infrecuente la co-localización de alopecia frontal fibrosante y vitiligo en un varón: informe de un caso / Infrequent phenomenon the co-localization of fibrosing frontal alopecia and vitiligo in a male: case repor

La alopecia frontal fibrosante es una alopecia cicatricial que se caracteriza por la recesión de la línea de implantación frontotemporal que afecta principalmente a mujeres caucásicas en edad posmenopáusica y rara vez a hombres. Actualmente los mecanismos específicos de desarrollo continúan en estudio; sin embargo hay varias hipótesis sobre la asociación de la alopecia frontal fibrosante con otros trastornos autoinmunitarios. Se comunica el caso de un paciente masculino de 58 años con alopecia frontal fibrosante en áreas comprometidas por vitiligo. (AU)

Frontal fibrosing alopecia is a cicatricial alopecic characterized by progressive regression of the frontotemporal hairline. It usually affects postmenopausal caucasian women, and rarely men. Currently the specific mechanisms of development remain unknown, however there are several hypotheses about the association of frontal fibrosing alopecia with other autoimmune disorders. The case of a 58-year-old male patient with frontal fibrosing alopecia in areas affected by vitiligo. (AU)

Carcinoma basocelular de couro cabeludo x alopecia frontal fibrosante: desafio diagnóstico e terapêutico / Basal cell carcinoma of the scalp x frontal fibrosing alopecia: diagnostic and therapeutic challenge

O carcinoma basocelular é considerado a neoplasia mais comum do mundo, tem como principal fator de risco a radiação ultravioleta, pode aparecer em todo o corpo incluindo couro cabeludo. A alopecia frontal fibrosante é uma alopecia cicatricial primária, variante do líquen planopilar. A associação entre as duas patologias não tem relato prévio na literatura. Neste caso apresenta-se paciente feminina, pós-menopausa, atendida por queixa de queda de cabelo, com diagnóstico histopatológico de alopecia frontal fibrosante e carcinoma basocelular de couro cabeludo. A distinção das margens tumorais para exérese completa da neoplasia é complexa apenas pela dermatoscopia e exame físico, devido á presença de áreas de atrofia em comum. Então se optou pela cirurgia micrográfica de Mohs para delimitação histopatológica de margens.

BCC is considered the most common neoplasia in the world, it can appear throughout the body including the scalp. Frontal fibrosing alopecia is a primary scarring alopecia, variant of lichen planopilaris. The association between the two pathologies has not been previously reported in the literature. In this case it is presented a brazilian female patient complaining of hair loss, with histopathological diagnosis of AFF and scalp BCC. The distinction of tumor margins for neoplastic excision is complex only by dermoscopy and physical examination, due to areas of common atrophy. So Mohs micrographic surgery was chosen for histopathological delimitation of margins.

Frontal Fibrosing Alopecia: A Retrospective Study of 75 Patients. / Alopecia frontal fibrosante: estudio retrospectivo de 75 pacientes.

BACKGROUND AND OBJECTIVE: Frontal fibrosing alopecia is an increasingly common form of scarring alopecia. The aim of this study was to describe the demographic and clinical characteristics of patients with FFA seen at the trichology unit of a medium-sized regional hospital and to report on treatments used. MATERIAL AND METHOD: We reviewed the medical records of all patients with FFA seen at the trichology unit of Hospital Universitario Infanta Sofía in Madrid, Spain between May 2016 and May 2018. We analyzed associations between disease severity, clinical patterns, need for oral medications, and other characteristics. RESULTS: Seventy-five patients (73 women and 2 men) were studied. Diagnosis was clinical in most cases and 13 cases (17.3%) were confirmed histologically. Median (interquartile range) age at reported onset of symptoms was 61 (12) years. Involvement of the eyebrows was recorded in 70 patients (93.3%) and signs of oral and genital lichen planus in 7 (9.6%). Eleven patients (14.7%) had hypothyroidism and 15 (20.0%) had signs of rosacea. Only 5 of the patients who presented a linear pattern (21.7%) had severe hairline recession. Patients with unstable and/or symptomatic disease (n=24) were treated with oral medications (5-alpha reductase inhibitors, hydroxychloroquine, corticosteroids, and isotretinoin) or intralesional corticosteroids. Eighteen patients (75.0%) achieved disease stability. Ten of the 15 patients with signs of rosacea and 10 of those with facial papules required systemic treatment. CONCLUSION: Most of the patients in this series of FFA were postmenopausal women. The prevalence of oral and genital lichen planus was higher than that observed in the general population. Patients with a linear pattern had less severe disease. Facial papules were more common in younger patients and both facial papules and rosacea were associated with a greater need for oral treatment.

Update on Frontal Fibrosing Alopecia. / Actualización en alopecia frontal fibrosante.

Frontal fibrosing alopecia (FFA) is an increasingly common acquired primary scarring alopecia, first described by Kossard in 1994. Clinically it is characterized by frontotemporal hairline recession, frequently accompanied by eyebrow loss. FFA was initially thought to have a hormonal origin as it was first described in postmenopausal women and premenopausal women with a history of hysterectomy or early menopause. This origin, however, has been questioned in recent years due to the publication of cases in men and premenopausal women. Although FFA has a highly characteristic clincal pattern, it is histologically similar to lichen planopilaris, and is currently believed to be a clinical variant of this condition. No clinical trials to date have investigated the efficacy of treatments for FFA. Numerous drugs, however, have been assessed in observational studies, and the best results to date have been reported for 5-αreductase inhibitors and intralesional corticosteroids, followed by antimalarials and calcineurin inhibitors. In this article, we review the latest data on the etiology, pathogenesis, clinical presentation, diagnosis, and treatment of FFA.

New Treatments for Hair Loss. / Novedades terapéuticas en tricología.

The treatment of hair loss is an important part of clinical dermatology given the prevalence of the problem and great impact on patients' quality of life. Many new treatments have been introduced in recent years. This review summarizes the main ones in 4 groups: a) For androgenetic alopecia, we discuss new excipients for oral minoxidil, dutasteride, and finasteride as well as new forms of topical application; prostaglandin agonists and antagonists; low-level laser therapy; and regenerative medicine with Wnt signaling activators and stem cell therapy. b) For alopecia areata, Janus kinase inhibitors are reviewed. c) For frontal fibrosing alopecia, we discuss the use of antiandrogens and, for some patients, pioglitazone. d) Finally, we mention new robotic devices for hair transplant procedures and techniques for optimal follicular unit extraction.

Frontal Fibrosing Alopecia in Men: Presentations in 12 Cases and a Review of the Literature. / Alopecia frontal fibrosante en el varón: presentación de 12 casos y revisión de la literatura.

BACKGROUND: Frontal fibrosing alopecia (FFA) is a scarring disease in which the hairline recedes and the eyebrows can be affected. Usually seen in postmenopausal women, FFA is much less common in men. OBJECTIVE: To describe the clinical characteristics of FFA in a case series of men and compare this series to those reported in the literature. MATERIAL AND METHODS: Men with FFA being treated in our dermatology department from January 2010 to December 2015 were included prospectively for this descriptive study. We collected patient information and clinical and treatment characteristics. RESULTS: Twelve men (mean age, 75 years) were recruited. Alopecia was the reason for seeking medical care in only 4 cases. The hairline had receded 3cm on average. Half the patients had facial papules, and 83% had androgenetic alopecia or hair loss on eyebrows or extremities. Follicular hyperkeratosis and erythema were present in 66%, and only 25% of the men reported pruritus. The most commonly prescribed treatments were topical: corticosteroids in 8 patients (66%) and minoxidil in 4 (33%). CONCLUSIONS: Facial papules, androgenetic alopecia, and loss of body hair are more often observed in men with FFA than in women. The men in this series were older on average than in other FFA case series in the literature, possibly accounting for the higher prevalence of associated androgenetic alopecia and the fact that most of these men were seeking care for conditions other than hair loss.